This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Mevacor

Merck & Co., Inc.

Drug Names(s): Lovastatin

Description: The active ingredient of Mevacor, Lovastatin, inhibits HMG-CoA reductase, an enzyme required for the synthesis of cholesterol. Mevacor has been shown to reduce the concentrations of both normal and elevated low density lipoprotein cholesterol (LDL).

Deal Structure: In November 2007, GlaxoSmithKline and Merck announced that the Companies have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR. Under the agreement, GSK will have exclusive rights to market non-prescription MEVACOR in the United States. Terms of the agreement are confidential but include milestone and royalty payments from GSK to Merck.


Mevacor News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug